LU92397I2 - Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable - Google Patents

Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable

Info

Publication number
LU92397I2
LU92397I2 LU92397C LU92397C LU92397I2 LU 92397 I2 LU92397 I2 LU 92397I2 LU 92397 C LU92397 C LU 92397C LU 92397 C LU92397 C LU 92397C LU 92397 I2 LU92397 I2 LU 92397I2
Authority
LU
Luxembourg
Prior art keywords
vortioxetine
pharmaceutically acceptable
acid addition
addition salt
acceptable acid
Prior art date
Application number
LU92397C
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92397(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of LU92397I2 publication Critical patent/LU92397I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU92397C 2001-10-04 2014-03-12 Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable LU92397I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04

Publications (1)

Publication Number Publication Date
LU92397I2 true LU92397I2 (fr) 2014-05-12

Family

ID=8160750

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92397C LU92397I2 (fr) 2001-10-04 2014-03-12 Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable

Country Status (38)

Country Link
US (10) US7144884B2 (fr)
EP (2) EP1749818B1 (fr)
JP (3) JP3896116B2 (fr)
KR (3) KR100783346B1 (fr)
CN (1) CN1319958C (fr)
AR (2) AR036659A1 (fr)
AT (2) ATE441631T1 (fr)
AU (2) AU2002333220C1 (fr)
BE (1) BE2014C036I2 (fr)
BR (3) BR122012009534C8 (fr)
CA (1) CA2462110C (fr)
CO (1) CO5580746A2 (fr)
CY (3) CY1107924T1 (fr)
DE (2) DE60225162T3 (fr)
DK (2) DK1749818T3 (fr)
EA (2) EA011096B1 (fr)
EG (1) EG25095A (fr)
ES (2) ES2298425T7 (fr)
FR (1) FR14C0033I2 (fr)
HR (1) HRP20040220A2 (fr)
HU (3) HU228956B1 (fr)
IL (1) IL160655A0 (fr)
IS (2) IS2578B (fr)
LT (1) LTC1436271I2 (fr)
LU (1) LU92397I2 (fr)
ME (1) ME00039B (fr)
MX (1) MXPA04002959A (fr)
MY (1) MY140950A (fr)
NL (1) NL300652I2 (fr)
NO (3) NO326443B1 (fr)
NZ (1) NZ531556A (fr)
PL (2) PL209253B1 (fr)
PT (2) PT1436271E (fr)
RS (2) RS52326B (fr)
SI (1) SI1436271T1 (fr)
UA (2) UA81749C2 (fr)
WO (1) WO2003029232A1 (fr)
ZA (1) ZA200401583B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
AR043966A1 (es) * 2003-04-04 2005-08-17 Lundbeck & Co As H Derivados de 4- ( 2-feniloxifenil) - piperidina o 1,2,3,6 -tetrahidropiridina como inhibidores de la recaptacion de la serotonina
DE602004013314T2 (de) * 2003-04-04 2008-08-07 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6-tetrahydropyridin-derivate als serotonin-wiederaufnahme-hemmer
ZA200507181B (en) * 2003-04-04 2007-03-28 Lundbeck & Co As 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
CA2521258C (fr) * 2003-04-04 2009-12-01 H. Lundbeck A/S Derives 4-(2-phenylsulfanyl-phenyl)-piperidines utilises en tant qu'inhibiteurs de reabsorption de la serotonine
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
AU2004303461B2 (en) 2003-12-23 2011-04-28 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
ATE435216T1 (de) * 2005-02-10 2009-07-15 Neurosearch As Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
SI2044020T1 (sl) * 2006-06-16 2011-06-30 Lundbeck & Co As H Kristaliniäśne oblike 4-(2-(4-metilfenilsulfanil)-fenil)piperidina s kombiniranim zaviranjem ponovnega privzema serotonina in norepinefrina za zdravljenje nevropatske boleäśine
BR122020011920A2 (pt) * 2006-06-16 2020-08-25 Lundbeck & Co As H composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
ES2361949T3 (es) * 2006-06-16 2011-06-24 H. Lundbeck A/S Formas cristalinas de 4-[2-(4-metilfenilsulfanil)-fenil]piperidina con inhibición de la reabsorción de serotonina y norepinefrina combinada para el tratamiento del dolor neuropático.
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
HRP20140044T1 (hr) 2007-06-15 2014-02-14 H. Lundbeck A/S 4-[2-(4-metilfenilsulfanil)fenil]piperidin za lijeäśenje iritabilnog sindroma crijeva (ibs)
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2009081259A1 (fr) * 2007-12-21 2009-07-02 Pfizer Inc. Dérivés phénoxy-pyridylés
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
WO2010056938A1 (fr) 2008-11-14 2010-05-20 Theravance, Inc. Procédé de préparation de composés à base de 4-[2-(2-fluorophénoxy­méthyl)phényl]pipéridine
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
GEP20135938B (en) * 2009-04-24 2013-10-10 H Lundbeck As Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine
MX2012002199A (es) * 2009-08-24 2012-03-16 Lundbeck & Co As H Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina.
WO2011053706A1 (fr) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Modulateurs des récepteurs aux opioïdes delta 4-substitué-2-phénoxy-phénylamine
WO2011085291A1 (fr) * 2010-01-11 2011-07-14 Theravance, Inc. Composés de type 1-(2-phénoxyméthylphényl)pipérazine comme inhibiteurs du recaptage de la sérotonine et de la norépinéphrine
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
CN103096879B (zh) 2010-04-30 2014-12-10 武田药品工业株式会社 肠溶片剂
WO2011136376A1 (fr) * 2010-04-30 2011-11-03 武田薬品工業株式会社 Comprimé à délitage intestinal
EP2407467A1 (fr) 2010-07-14 2012-01-18 Sandoz Ag Composés cristallins de 1-[4-(2-azépan-1-yl-éthoxy)-benzyl]-2-(4-hydroxyphényl)-3-méthyl-1H-indol-5-ol et d'acide lactique
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR101879474B1 (ko) 2011-06-20 2018-07-17 하. 룬드벡 아크티에셀스카브 정신 분열증의 치료를 위한 중수소화 1-피페라지노-3-페닐 인단
WO2013074676A2 (fr) 2011-11-14 2013-05-23 The General Hospital Corporation Dosages et procédés pour la sélection d'un schéma thérapeutique pour un sujet atteint d'une dépression
LT2800746T (lt) * 2012-01-03 2019-06-10 H. Lundbeck A/S 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazino gavimo būdas
CN104797566B (zh) 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
CN104853755B (zh) 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
CN104995181B (zh) * 2013-02-22 2017-03-08 H.隆德贝克有限公司 沃替西汀生产方法
EP2981520B1 (fr) 2013-04-04 2019-03-06 LEK Pharmaceuticals d.d. Nouveau procédé de synthèse de la 1-(2-((2,4-dimethylphenyl)thio)phenyl)pipérazine
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
WO2015044963A1 (fr) 2013-09-30 2015-04-02 Cadila Healthcare Limited Vortioxétine amorphe et sels de ladite substance
EP2878596A1 (fr) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthèse de vortioxetine via des intermédiaires de (2-(pipérazine-1-yl)phényl)lithium
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
CA2933733A1 (fr) 2013-12-20 2015-06-25 Connie Sanchez Morillo Utilisation d'un antagoniste du recepteur opioide presentant une activite kappa et de vortioxetine dans le traitement de trouble depressif avec caracteristiques melancoliques
EP2894154A1 (fr) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthèse de vortioxetine via des intermédiaires de (2-(piperazine-1-yl)phényl)aniline
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
WO2015114395A1 (fr) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Procédé de préparation de sels de vortioxétine
EP2930171A1 (fr) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthèse de vortioxetine via intermédiaire de (2,4-diméthylphényl) (2-iodophényl)sulfane
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (fr) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. Procédé de préparation de vortioxétine et de polymorphes de cette substance
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (fr) 2015-02-04 2016-08-11 Mylan Laboratories Limited Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci
WO2016125191A2 (fr) 2015-02-04 2016-08-11 Mylan Laboratories Limited Procédés de préparation de bromhydrate de vortioxétine
AU2016224930A1 (en) 2015-02-25 2017-09-07 Lupin Limited Process for the preparation of Vortioxetine
EP3274330A1 (fr) 2015-03-26 2018-01-31 Cipla Limited Procédé de fabrication d'inhibiteurs de la recapture de la sérotonine
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CN108348486A (zh) * 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
EP3337789A1 (fr) * 2015-08-19 2018-06-27 Amneal Pharmaceuticals Company GmbH Procédé de préparation de bromhydrate de vortioxétine
EP3362058B1 (fr) * 2015-10-14 2021-09-01 Institut Pasteur Agent de stimulation du récepteur 5-hydroxytryptamine 1b pour le traitement de l'infarctus du myocarde
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (fr) 2016-03-21 2017-09-28 H. Lundbeck A/S Promédicaments de vortioxétine
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US20190290641A1 (en) * 2016-07-15 2019-09-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
KR20190032418A (ko) * 2016-07-22 2019-03-27 지앙수 인화뤄캉 파마슈티컬 리서치 앤드 디벨롭먼트 컴퍼니 리미티드 보티옥세틴 유사체와 용도 및 이의 제조
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
US11020390B2 (en) 2017-02-17 2021-06-01 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
EP3585388A4 (fr) 2017-02-23 2020-08-12 Unichem Laboratories Ltd Procédé amélioré de préparation et de purification de bromhydrate de vortioxétine
KR102551433B1 (ko) 2017-04-25 2023-07-04 하. 룬드벡 아크티에셀스카브 보르티옥세틴 hbr 알파-형태의 제조 방법
EP3412661A1 (fr) 2017-06-08 2018-12-12 Enantia, S.L. Co-cristaux de bromhydrate vortioxetine et du résorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
PT3810582T (pt) 2018-06-20 2024-04-09 Vio Ag Pharmaceuticals S A Uma abordagem de ativação de c-h organo-pseudocatalítica em um só recipiente para a preparação de vortioxetina e intermediário de vortioxetina
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
WO2020087031A1 (fr) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
AU2021246973A1 (en) 2020-04-03 2022-11-03 H. Lundbeck A/S 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting
US12281088B2 (en) 2020-09-10 2025-04-22 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Process for the synthesis of vortioxetine
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (fr) 2023-12-21 2025-06-26 H. Lundbeck A/S Procédé de préparation de compositions pharmaceutiques de vortioxétine présentant de faibles quantités d'impuretés de nitrosamine
CN120774863A (zh) * 2024-04-02 2025-10-14 王春刚 一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151751B1 (fr) 1971-04-13 1973-11-19
CS151755B1 (fr) 1971-04-13 1973-11-19
CS151752B1 (fr) 1971-04-13 1973-11-19
CS151753B1 (fr) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
ATE294778T1 (de) 1995-01-23 2005-05-15 Daiichi Suntory Pharma Co Ltd Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2681877A1 (fr) * 1997-10-31 1999-05-14 Asubio Pharma Co., Ltd. Rylpiperidinopropanol et derives d'arylpiperazinopropanol et produits pharmaceutiques contenant lesdits composes
EA200101017A1 (ru) 1999-04-02 2002-04-25 Айкос Корпорейшен Ингибиторы связывания lfa-1 с icam и их использование
BR0012984A (pt) 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
IL148677A0 (en) * 1999-09-14 2002-09-12 Pharmacopeia Inc Article comprising a multi-channel dispensing head
MXPA02006223A (es) * 1999-12-30 2002-12-05 Lundbeck & Co As H Derivados de fenilpiperazina sustituida, su preparcion y uso.
WO2001049681A1 (fr) 1999-12-30 2001-07-12 H. Lundbeck A/S Procede de preparation de derives de benzene substitue
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
CA2431996A1 (fr) * 2001-01-23 2002-08-01 Vincent Mancuso Derives de piperazine agonistes du recepteur de la melanocortine
EP1363890A4 (fr) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60219521T2 (de) * 2001-12-20 2007-08-16 H. Lundbeck A/S Aryloxyphenyl und arylsulfanylphenylderivate
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CA2521258C (fr) * 2003-04-04 2009-12-01 H. Lundbeck A/S Derives 4-(2-phenylsulfanyl-phenyl)-piperidines utilises en tant qu'inhibiteurs de reabsorption de la serotonine
WO2005000309A2 (fr) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Composes chimiques
BR122020011920A2 (pt) * 2006-06-16 2020-08-25 Lundbeck & Co As H composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto

Also Published As

Publication number Publication date
ES2328725T3 (es) 2009-11-17
PL210551B1 (pl) 2012-02-29
AU2002333220C1 (en) 2023-10-05
DK1749818T3 (da) 2009-10-12
AU2006215994B2 (en) 2008-11-13
BR122012009534B8 (pt) 2019-01-29
HU230189B1 (hu) 2015-09-28
CN1319958C (zh) 2007-06-06
US20060084662A1 (en) 2006-04-20
ME00039B (fr) 2010-06-10
ATE441631T1 (de) 2009-09-15
BR122012023120B8 (pt) 2022-01-18
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
US7683053B2 (en) 2010-03-23
US20140163043A1 (en) 2014-06-12
KR20040047886A (ko) 2004-06-05
NO2014011I2 (no) 2015-08-31
FR14C0033I1 (fr) 2014-06-13
KR100770194B1 (ko) 2007-10-25
DK1436271T6 (da) 2022-06-27
CY2014022I2 (el) 2015-12-09
AU2006215994A9 (en) 2006-10-05
KR100842702B1 (ko) 2008-07-01
ES2298425T3 (es) 2008-05-16
LTC1436271I2 (lt) 2016-09-12
DE60225162D1 (de) 2008-04-03
AR036659A1 (es) 2004-09-22
CY1110064T1 (el) 2015-01-14
UA93857C2 (uk) 2011-03-25
NO332355B1 (no) 2012-09-03
US8476279B2 (en) 2013-07-02
US20070060574A1 (en) 2007-03-15
EP1749818A3 (fr) 2008-04-02
ATE386730T1 (de) 2008-03-15
MY140950A (en) 2010-02-12
US7144884B2 (en) 2006-12-05
CA2462110A1 (fr) 2003-04-10
ES2298425T7 (es) 2022-06-27
NL300652I1 (fr) 2016-01-18
AU2006215994A2 (en) 2006-10-05
CY2014022I1 (el) 2015-12-09
RS52865B (sr) 2013-12-31
US20160137620A1 (en) 2016-05-19
KR100783346B1 (ko) 2007-12-07
NZ531556A (en) 2005-12-23
RS52326B (sr) 2012-12-31
CO5580746A2 (es) 2005-11-30
CA2462110C (fr) 2010-05-11
CN1561336A (zh) 2005-01-05
CA2462110E (fr) 2003-04-10
PT1436271E (pt) 2008-04-10
UA81749C2 (uk) 2008-02-11
US20180127389A1 (en) 2018-05-10
IS2732B (is) 2011-04-15
BE2014C036I2 (fr) 2021-11-22
RS20120158A3 (en) 2013-10-31
SI1436271T1 (sl) 2008-06-30
PL368442A1 (pl) 2005-03-21
MXPA04002959A (es) 2004-07-05
DK1436271T3 (da) 2008-06-09
BR0212733B1 (pt) 2014-05-13
EA200400498A1 (ru) 2004-08-26
JP2005505585A (ja) 2005-02-24
HUP0402313A3 (en) 2010-03-29
US7148238B2 (en) 2006-12-12
PL209253B1 (pl) 2011-08-31
US20110009423A1 (en) 2011-01-13
BR0212733A (pt) 2004-11-16
LTPA2014013I1 (lt) 2014-04-25
EP1749818B1 (fr) 2009-09-02
JP3955614B2 (ja) 2007-08-08
AU2002333220A2 (en) 2003-04-14
US20210276966A1 (en) 2021-09-09
US20050014740A1 (en) 2005-01-20
RS20120158A2 (sr) 2012-10-31
MEP6508A (xx) 2010-02-10
US20120302553A1 (en) 2012-11-29
RS27704A (sr) 2006-10-27
HRP20040220A2 (en) 2005-02-28
US10844029B2 (en) 2020-11-24
CY1107924T1 (el) 2013-09-04
EP1436271B1 (fr) 2008-02-20
BR122012009534B1 (pt) 2018-02-27
NO20083446L (no) 2004-04-21
EP1436271A1 (fr) 2004-07-14
JP3896116B2 (ja) 2007-03-22
BRPI0212733B8 (pt) 2021-05-25
DE60233608D1 (de) 2009-10-15
EA007537B1 (ru) 2006-10-27
IS2578B (is) 2010-02-15
NO20041628L (no) 2004-04-21
WO2003029232A1 (fr) 2003-04-10
PT1749818E (pt) 2009-10-06
EA200601269A1 (ru) 2007-02-27
KR20070103515A (ko) 2007-10-23
AU2002333220B2 (en) 2008-02-07
IL160655A0 (en) 2004-07-25
NO326443B1 (no) 2008-12-08
AR066460A2 (es) 2009-08-19
HK1072600A1 (zh) 2005-09-02
IS7164A (is) 2004-02-26
FR14C0033I2 (fr) 2014-11-14
NO2014011I1 (no) 2014-05-13
ZA200401583B (en) 2005-05-25
JP3955613B2 (ja) 2007-08-08
JP2007051149A (ja) 2007-03-01
HU228956B1 (en) 2013-07-29
EP1436271B3 (fr) 2022-04-20
US7138407B2 (en) 2006-11-21
AU2006215994A1 (en) 2006-10-05
KR20060118020A (ko) 2006-11-17
NL300652I2 (fr) 2016-01-18
HUS1400012I1 (hu) 2020-12-28
EA007537B3 (ru) 2015-02-27
EG25095A (en) 2011-08-17
HUP0402313A2 (hu) 2005-02-28
EA011096B1 (ru) 2008-12-30
DE60225162T2 (de) 2009-02-12
EP1749818A2 (fr) 2007-02-07
US8110567B2 (en) 2012-02-07
BR122012023120B1 (pt) 2017-03-21
US9708280B2 (en) 2017-07-18
JP2007031447A (ja) 2007-02-08
IS8806A (is) 2009-03-10
US20060089368A1 (en) 2006-04-27
US9090575B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
LU92397I2 (fr) Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
LU92520I2 (fr) Bédaquiline, ou son sel d'addition d'acide ou de base pharmaceutiquement acceptable, y compris le fumarate de bédaquiline
EP1352332A4 (fr) Systeme d'exception directe
LU92880I2 (fr) Evérolimus ou un sel pharmaceutiquement acceptablequi en dérive (afinitor)
LU92943I2 (fr) Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa)
FR2817306B1 (fr) Systeme d'entrainement
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
DE60044625D1 (de) Système d'assistance de conduire pour vehicules
LU92826I2 (fr) Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone
EP1286136A4 (fr) Transducteur d'inertie
IL161736A0 (en) Novel benzophenone derivatives or salts thereof
MA25984A1 (fr) Procede pour preparation de maleate d'amlodipine.
EP1293131A4 (fr) Agents therapeutiques pour la gorge
ECSP045162A (es) "composiciones farmaceuticas a base de derivados de azetidina"
FR2818979B1 (fr) Procede de preparation d'imidaclopride
EE200200554A (et) Galantamiini või selle farmatseutiliselt sobiva soola kasutamine
ITMI20012197A0 (it) Sistema di ausilio all'arbitraggio di un incontro di calcio
GB0012123D0 (en) Alzheimer's disease assay
AU2002364885A1 (en) Alzheimer's disease model
PL368419A1 (en) Novel $g(a)-oxygenated or $g(a)-thiolated carboxylic acid phenethylamide derivatives
MA25828A1 (fr) Procede de preparation d'oligomeres de galactomannanes
ITMI20000810A0 (it) Procedimento per la preparazione di 5'-acetilstavudina
FR2829806B3 (fr) Ensemble d'helice perfectionne
ES1044904Y (es) "badajo"